Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer

Nasser Hanna, Rogerio Lilenbaum, Rafat Ansari, Thomas Lynch, Ramaswamy Govindan, Pasi A. Jänne, Philip Bonomi

Research output: Contribution to journalArticle

174 Citations (Scopus)

Abstract

Purpose: To determine the efficacy of cetuximab in patients with recurrent or progressive non-small-cell lung cancer (NSCLC) after receiving at least one prior chemotherapy regimen. Patients and Methods: This was an open-label, phase II study of patients with epidermal growth factor receptor (EGFR) -positive and EGFR-negative advanced NSCLC with Eastern Cooperative Oncology Group performance status 0 to 1. Patients received cetuximab 400 mg/m2 intravenously (IV) during 120 minutes on week 1 followed by weekly doses of cetuximab 250 mg/m2 IV during 60 minutes. A cycle was considered as 4 weeks of treatment and therapy was continued until disease progression or intolerable toxicities. The primary end point was to assess response rate. Secondary end points included an estimation of time to progression and survival. Results: Patient and disease characteristics (n = 66) included EGFR-positive status (n = 60); EGFR-negative status (n = 6); number of prior regimens (one, n = 28; two, n = 27; ≥ three, n = 11); male (n = 41); female (n = 25); adenocarcinoma (n = 36); and smoking status (never, n = 13; former, n = 45; current, n = 8). Grade 3/4 toxicities included acne-like rash (6.1%), anaphylactic reactions (1.5%), and diarrhea (1.5%). The response rate for all patients (n = 66) was 4.5% (95% CI, 0.9% to 12.7%) and the stable disease rate was 30.3% (95% CI, 19.6% to 42.9%). The response rate for patients with EGFR-positive tumors (n = 60) was 5% (95% CI, 1.0% to 13.9%). The median time to progression for all patients was 2.3 months (95% CI, 2.1 to 2.6 months) and median survival time was 8.9 months (95% CI, 6.2 to 12.6 months). Conclusion: Although the response rate with single-agent cetuximab in this heavily pretreated patient population with advanced NSCLC was only 4.5%, the disease control rates and overall survival seem comparable to that of pemetrexed, docetaxel, and erlotinib in similar groups of patients.

Original languageEnglish
Pages (from-to)5253-5258
Number of pages6
JournalJournal of Clinical Oncology
Volume24
Issue number33
DOIs
StatePublished - Nov 20 2006

Fingerprint

Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
docetaxel
Pemetrexed
Cetuximab
Survival
Acne Vulgaris
Anaphylaxis
Exanthema
Disease Progression
Diarrhea
Adenocarcinoma
Survival Rate
Smoking
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Hanna, N., Lilenbaum, R., Ansari, R., Lynch, T., Govindan, R., Jänne, P. A., & Bonomi, P. (2006). Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. Journal of Clinical Oncology, 24(33), 5253-5258. https://doi.org/10.1200/JCO.2006.08.2263

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. / Hanna, Nasser; Lilenbaum, Rogerio; Ansari, Rafat; Lynch, Thomas; Govindan, Ramaswamy; Jänne, Pasi A.; Bonomi, Philip.

In: Journal of Clinical Oncology, Vol. 24, No. 33, 20.11.2006, p. 5253-5258.

Research output: Contribution to journalArticle

Hanna, N, Lilenbaum, R, Ansari, R, Lynch, T, Govindan, R, Jänne, PA & Bonomi, P 2006, 'Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer', Journal of Clinical Oncology, vol. 24, no. 33, pp. 5253-5258. https://doi.org/10.1200/JCO.2006.08.2263
Hanna, Nasser ; Lilenbaum, Rogerio ; Ansari, Rafat ; Lynch, Thomas ; Govindan, Ramaswamy ; Jänne, Pasi A. ; Bonomi, Philip. / Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 33. pp. 5253-5258.
@article{d28fb6e5062d4ae0ab7b2584f92f1a64,
title = "Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer",
abstract = "Purpose: To determine the efficacy of cetuximab in patients with recurrent or progressive non-small-cell lung cancer (NSCLC) after receiving at least one prior chemotherapy regimen. Patients and Methods: This was an open-label, phase II study of patients with epidermal growth factor receptor (EGFR) -positive and EGFR-negative advanced NSCLC with Eastern Cooperative Oncology Group performance status 0 to 1. Patients received cetuximab 400 mg/m2 intravenously (IV) during 120 minutes on week 1 followed by weekly doses of cetuximab 250 mg/m2 IV during 60 minutes. A cycle was considered as 4 weeks of treatment and therapy was continued until disease progression or intolerable toxicities. The primary end point was to assess response rate. Secondary end points included an estimation of time to progression and survival. Results: Patient and disease characteristics (n = 66) included EGFR-positive status (n = 60); EGFR-negative status (n = 6); number of prior regimens (one, n = 28; two, n = 27; ≥ three, n = 11); male (n = 41); female (n = 25); adenocarcinoma (n = 36); and smoking status (never, n = 13; former, n = 45; current, n = 8). Grade 3/4 toxicities included acne-like rash (6.1{\%}), anaphylactic reactions (1.5{\%}), and diarrhea (1.5{\%}). The response rate for all patients (n = 66) was 4.5{\%} (95{\%} CI, 0.9{\%} to 12.7{\%}) and the stable disease rate was 30.3{\%} (95{\%} CI, 19.6{\%} to 42.9{\%}). The response rate for patients with EGFR-positive tumors (n = 60) was 5{\%} (95{\%} CI, 1.0{\%} to 13.9{\%}). The median time to progression for all patients was 2.3 months (95{\%} CI, 2.1 to 2.6 months) and median survival time was 8.9 months (95{\%} CI, 6.2 to 12.6 months). Conclusion: Although the response rate with single-agent cetuximab in this heavily pretreated patient population with advanced NSCLC was only 4.5{\%}, the disease control rates and overall survival seem comparable to that of pemetrexed, docetaxel, and erlotinib in similar groups of patients.",
author = "Nasser Hanna and Rogerio Lilenbaum and Rafat Ansari and Thomas Lynch and Ramaswamy Govindan and J{\"a}nne, {Pasi A.} and Philip Bonomi",
year = "2006",
month = "11",
day = "20",
doi = "10.1200/JCO.2006.08.2263",
language = "English",
volume = "24",
pages = "5253--5258",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "33",

}

TY - JOUR

T1 - Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer

AU - Hanna, Nasser

AU - Lilenbaum, Rogerio

AU - Ansari, Rafat

AU - Lynch, Thomas

AU - Govindan, Ramaswamy

AU - Jänne, Pasi A.

AU - Bonomi, Philip

PY - 2006/11/20

Y1 - 2006/11/20

N2 - Purpose: To determine the efficacy of cetuximab in patients with recurrent or progressive non-small-cell lung cancer (NSCLC) after receiving at least one prior chemotherapy regimen. Patients and Methods: This was an open-label, phase II study of patients with epidermal growth factor receptor (EGFR) -positive and EGFR-negative advanced NSCLC with Eastern Cooperative Oncology Group performance status 0 to 1. Patients received cetuximab 400 mg/m2 intravenously (IV) during 120 minutes on week 1 followed by weekly doses of cetuximab 250 mg/m2 IV during 60 minutes. A cycle was considered as 4 weeks of treatment and therapy was continued until disease progression or intolerable toxicities. The primary end point was to assess response rate. Secondary end points included an estimation of time to progression and survival. Results: Patient and disease characteristics (n = 66) included EGFR-positive status (n = 60); EGFR-negative status (n = 6); number of prior regimens (one, n = 28; two, n = 27; ≥ three, n = 11); male (n = 41); female (n = 25); adenocarcinoma (n = 36); and smoking status (never, n = 13; former, n = 45; current, n = 8). Grade 3/4 toxicities included acne-like rash (6.1%), anaphylactic reactions (1.5%), and diarrhea (1.5%). The response rate for all patients (n = 66) was 4.5% (95% CI, 0.9% to 12.7%) and the stable disease rate was 30.3% (95% CI, 19.6% to 42.9%). The response rate for patients with EGFR-positive tumors (n = 60) was 5% (95% CI, 1.0% to 13.9%). The median time to progression for all patients was 2.3 months (95% CI, 2.1 to 2.6 months) and median survival time was 8.9 months (95% CI, 6.2 to 12.6 months). Conclusion: Although the response rate with single-agent cetuximab in this heavily pretreated patient population with advanced NSCLC was only 4.5%, the disease control rates and overall survival seem comparable to that of pemetrexed, docetaxel, and erlotinib in similar groups of patients.

AB - Purpose: To determine the efficacy of cetuximab in patients with recurrent or progressive non-small-cell lung cancer (NSCLC) after receiving at least one prior chemotherapy regimen. Patients and Methods: This was an open-label, phase II study of patients with epidermal growth factor receptor (EGFR) -positive and EGFR-negative advanced NSCLC with Eastern Cooperative Oncology Group performance status 0 to 1. Patients received cetuximab 400 mg/m2 intravenously (IV) during 120 minutes on week 1 followed by weekly doses of cetuximab 250 mg/m2 IV during 60 minutes. A cycle was considered as 4 weeks of treatment and therapy was continued until disease progression or intolerable toxicities. The primary end point was to assess response rate. Secondary end points included an estimation of time to progression and survival. Results: Patient and disease characteristics (n = 66) included EGFR-positive status (n = 60); EGFR-negative status (n = 6); number of prior regimens (one, n = 28; two, n = 27; ≥ three, n = 11); male (n = 41); female (n = 25); adenocarcinoma (n = 36); and smoking status (never, n = 13; former, n = 45; current, n = 8). Grade 3/4 toxicities included acne-like rash (6.1%), anaphylactic reactions (1.5%), and diarrhea (1.5%). The response rate for all patients (n = 66) was 4.5% (95% CI, 0.9% to 12.7%) and the stable disease rate was 30.3% (95% CI, 19.6% to 42.9%). The response rate for patients with EGFR-positive tumors (n = 60) was 5% (95% CI, 1.0% to 13.9%). The median time to progression for all patients was 2.3 months (95% CI, 2.1 to 2.6 months) and median survival time was 8.9 months (95% CI, 6.2 to 12.6 months). Conclusion: Although the response rate with single-agent cetuximab in this heavily pretreated patient population with advanced NSCLC was only 4.5%, the disease control rates and overall survival seem comparable to that of pemetrexed, docetaxel, and erlotinib in similar groups of patients.

UR - http://www.scopus.com/inward/record.url?scp=33947415279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947415279&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.08.2263

DO - 10.1200/JCO.2006.08.2263

M3 - Article

C2 - 17114658

AN - SCOPUS:33947415279

VL - 24

SP - 5253

EP - 5258

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 33

ER -